Recent efforts have expanded toward the development of radioligands for imaging non-AD tauopathies, which are critical for advancing diagnosis and understanding disease mechanisms across the broader spectrum of tau-related neurodegeneration. This evidence concerns the gene MAPT and Alzheimer disease.